AA
BCRX icon

ALPS Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

ALPS Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
317,960
+257,710
+428% +$2.33M 0.01% 385
2026
Q1 		$574K Buy
+60,250
New +$468K ﹤0.01% 676
2025
Q4 		– Sell
-101,125
Closed -$768K – 1021
2025
Q3 		$768K Sell
101,125
-11,710
-10% -$97.5K ﹤0.01% 611
2025
Q2 		$1.01M Sell
112,835
-40,150
-26% -$374K 0.01% 498
2025
Q1 		$1.15M Sell
152,985
-14,507
-9% -$117K 0.01% 447
2024
Q4 		$1.26M Buy
167,492
+9,382
+6% +$71.2K 0.01% 432
2024
Q3 		$1.2M Sell
158,110
-2,893
-2% -$22K 0.01% 456
2024
Q2 		$995K Buy
161,003
+15,597
+11% +$86.1K 0.01% 465
2024
Q1 		$739K Buy
145,406
+7,305
+5% +$41.1K 0.01% 546
2023
Q4 		$827K Sell
138,101
-1,749
-1% -$10.1K 0.01% 522
2023
Q3 		$990K Buy
139,850
+972
+0.7% +$6.98K 0.01% 450
2023
Q2 		$978K Buy
138,878
+16,060
+13% +$129K 0.01% 501
2023
Q1 		$1.02M Sell
122,818
-3,555
-3% -$34.2K 0.01% 465
2022
Q4 		$1.45M Buy
126,373
+24,834
+24% +$310K 0.01% 363
2022
Q3 		$1.28M Sell
101,539
-8,576
-8% -$110K 0.01% 393
2022
Q2 		$1.17M Buy
+110,115
New +$1.14M 0.01% 442
2018
Q2 		– Sell
-132,021
Closed -$630K – 931
2018
Q1 		$630K Buy
132,021
+22,977
+21% +$118K 0.01% 408
2017
Q4 		$535K Buy
109,044
+29,841
+38% +$145K ﹤0.01% 485
2017
Q3 		$415K Buy
79,203
+6,612
+9% +$33.9K ﹤0.01% 692
2017
Q2 		$404K Buy
+72,591
New +$442K ﹤0.01% 678
2016
Q2 		– Sell
-82,476
Closed -$233K – 612
2016
Q1 		$233K Sell
82,476
-14,134
-15% -$62.6K ﹤0.01% 593
2015
Q4 		$997K Buy
+96,610
New +$961K 0.01% 217

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ALPS Advisors's BCRX Position: Q2 2026 in Review

ALPS Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 428% in Q2 2026, buying an estimated $2.33M and bringing the position to 317,960 shares worth $3.18M. The position accounts for 0.01% of the portfolio, ranked #385.

ALPS Advisors first reported a position in BCRX in Q4 2015 and has held it in 22 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • ALPS Advisors held 317,960 shares of BioCryst Pharmaceuticals worth $3.18M as of Q2 2026.
  • ALPS Advisors bought 257,710 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.33M.
  • BioCryst Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #385 holding.
  • ALPS Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 22 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.